Recent News Releases
For investor-related news, see our ASX releases here.
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 2, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Release
-
Sep 1, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Aug 30, 2016The U.S. Food and Drug Administration (FDA) has accepted CSL Behring’s application for its low volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy for treating HAE. Upon FDA approval, CSL830 will be the first and only low volume, subcutaneous, prophylactic treatment option for HAE patients.
30 Aug 2016 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for its low-volume subcutaneous...
-
Aug 9, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Aug 4, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
Filter by Company:
Get our latest news releases in your inbox